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Introduction
Fibronectin (Fn) is required for mammalian development and 
for blood vessel formation (George et al., 1993, 1997; Hynes, 
1994; Peters and Hynes, 1996; Francis et al., 2002). Fn exists in 
both a soluble form in the plasma and as insoluble disulfi  de-
bonded multimers in the extracellular matrix. The insoluble ma-
trix form of Fn is essential for most of its biological functions in 
events such as wound healing, embryogenesis, and formation of 
the tumor microenvironment (Grinnell, 1984; Mosher, 1984; 
Ruoslahti, 1984). The soluble form of Fn is converted to the in-
soluble form by a process termed Fn matrix assembly, an active 
cellular process in which the soluble, dimeric Fn molecules 
are assembled into an insoluble, fi  brillar pericellular matrix. 
Thus, an understanding of Fn matrix assembly is of broad bio-
logical signifi  cance.
Pioneering studies (McKeown-Longo and Mosher, 1983, 
1985; Schwarzbauer, 1991; Sottile and Mosher, 1993; Sechler 
et al., 1996, 2001) have defi  ned the regions of Fn important in 
the assembly process. The N-terminal 70-kD domain of Fn 
plays a pivotal role in matrix assembly. It does so by inter-
acting with several other sites within the Fn molecule. These 
sites, which are generally contained within the type III repeats, 
are cryptic in soluble Fn and exposed as a consequence of 
conformational changes in Fn (Wierzbicka-Patynowski and 
Schwarzbauer, 2003). These conformational changes may in-
volve extension of the Fn or unfolding of particular repeats. 
Studies from several laboratories show that Fn conformation 
can be changed by mechanical deformation (Zhong et al., 
1998; Krammer et al., 1999; Erickson, 1994, 2002; Ohashi et al., 
2002). Indeed, the hypothesis that matrix assembly site expo-
sure is initiated by integrin-dependent mechanical deformation 
of Fn (Wu et al., 1995c) has been experimentally validated 
(Zhong et al., 1998). Thus, the assembly of an Fn matrix results 
from Fn–Fn interactions initiated by mechanical deformation 
of the Fn molecule.
The binding of Fn to integrins, such as α5β1, initiates 
the matrix assembly process (Corbett and Schwarzbauer, 1999; 
Mao and Schwarzbauer, 2005). In particular, forces generated 
by the cytoskeleton and conveyed to Fn via integrins cause 
deformation of the Fn molecule (Zhong et al., 1998). For as-
sembly to begin, these integrins must (1) physically associate 
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ntegrin-dependent assembly of the ﬁ  bronectin  (Fn) 
matrix plays a central role in vertebrate development. 
We identify CD98hc, a membrane protein, as an impor-
tant component of the matrix assembly machinery both in 
vitro and in vivo. CD98hc was not required for biosynthesis 
of cellular Fn or the maintenance of the repertoire or af-
ﬁ  nity of cellular Fn binding integrins, which are important 
contributors to Fn assembly. Instead, CD98hc was in-
volved in the cell’s ability to exert force on the matrix and 
did so by dint of its capacity to interact with integrins to 
support downstream signals that lead to activation of 
RhoA small GTPase. Thus, we identify CD98hc as a mem-
brane protein that enables matrix assembly and establish 
that it functions by interacting with integrins to support 
RhoA-driven contractility. CD98hc expression can vary 
widely; our data show that these variations in CD98hc 
expression can control the capacity of cells to assemble 
an Fn matrix, a process important in development, wound 
healing, and tumorigenesis.
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with Fn, usually by binding it with high affi  nity (operationally 
 defi  ned as an “activated” integrin; Wu et al., 1995c), and (2) 
physically associate with the cytoskeleton (Wu et al., 1995c). 
Several signaling enzymes, including Src family kinases, pp125
FAK, 
Rho GTPases, and PI3 kinase, are also involved in the matrix 
assembly process (Wierzbicka-Patynowski and Schwarzbauer, 
2002). These same signaling enzymes can be regulated by inte-
grin ligation in a process referred to as outside-in integrin 
signaling (Boudreau and Jones, 1999; Arias-Salgado et al., 
2005; Shattil, 2005). Thus, it is possible that integrin signals 
that regulate kinases such as pp125
FAK could participate in the 
assembly process.
We recently found that CD98hc, a type II transmem-
brane protein, mediates outside-in integrin signaling (Féral 
et al., 2005). CD98hc has two distinct functions: (1) it can 
associate with and regulate the function of selected integrins 
and (2) it can regulate the expression and distribution of CD98 
light chains to modulate amino acid transport function. Each 
function depends on distinct domains within CD98hc, with 
the intracellular portion being required for interaction with 
integrins (Fenczik et al., 2001). Deletion of CD98hc in em-
bryonic stem (ES) cells impaired the formation of teratocarci-
nomas in vivo and many integrin-dependent functions in vitro 
because CD98hc is a contributor to integrin-dependent bio-
chemical signals (Féral et al., 2005). The role of CD98hc in 
integrin signaling suggested that it might participate in the 
Fn matrix assembly process. Here, we report that CD98hc is 
required for effi  cient Fn matrix assembly both in vitro and 
in vivo. Furthermore, deletion of CD98hc has little effect on 
Fn biosynthesis or integrin activation; instead, lack of CD98hc 
impairs outside-in integrin signals that result in RhoA-mediated 
cellular contractility necessary for Fn matrix assembly. Finally, 
the portion of CD98hc that interacts with integrins is neces-
sary and suffi  cient to support cellular contractility and Fn ma-
trix assembly. Thus, we fi  nd that CD98hc participates in Fn 
matrix assembly by mediating the outside-in integrin signals 
required for the contractile events that initiate and sustain Fn 
matrix assembly.
Results
CD98hc is involved in Fn assembly in vivo
To determine whether CD98 regulates matrix assembly in 
vivo, we examined the distribution of Fn in teratocarcinomas 
Figure 1. CD98hc  deﬁ  ciency blocks Fn ﬁ  bril assembly in vivo. 
(A) Fn assembly was analyzed by staining WT (left) and 
CD98hc-null (right) tumors with an anti-Fn antibody. Fn stain-
ing is in red, whereas the nuclei are in green. Staining of 
two independent tumors per genotype is shown. Although 
CD98hc-null tumors do not show Fn assembly, Fn ﬁ  brils can 
be seen outside the tumor region (arrows). (B) Neovasculari-
zation during tumor development. Sections of tumors (WT 
and CD98hc null) were harvested and stained to reveal blood 
vessels. Whole mounts of tissue samples were stained with 
ﬂ  uorescent IB4 lectin and analyzed by laser-scanning confo-
cal microscopy. Sections (z series) were merged, and the re-
sulting images are shown. (C) Immunoﬂ  uorescent staining of 
WT and CD98hc-null tumors for the endothelial cells marker 
PECAM-1 (red) and smooth muscle cells marker α-smooth 
muscle (SM) actin (green). CD98hc-null tumors exhibit poor 
endothelial cell and smooth muscle cell organization. Bars: 
(A and C) 50 μm; (B) 200 μm.CD98HC (SLC3A2) AND FIBRONECTIN MATRIX • FÉRAL ET AL. 703
formed in nude mice after subcutaneous injection of ES cells. 
As previously reported, injection of wild-type (WT) ES cells 
into nude mice led to the formation of large tumors. In con-
trast, CD98hc-null cells either did not form tumors or formed 
very small tumors (Féral et al., 2005). The CD98hc-null tu-
mors that formed exhibited profound reduction in Fn fi  brils, as 
judged by staining with a mAb against Fn (Fig. 1 A). In con-
trast, a prominent network of Fn was detected in the tumors 
formed by WT ES cells. Thus, CD98hc is involved in Fn ma-
trix formation in vivo. Importantly, these CD98hc-null tera-
tocarcinomas, like those formed from WT ES cells contain 
tissues from all three germ layers. Furthermore, absence of 
CD98hc is compatible with differentiation of multiple cellular 
lineages (Féral et al., 2005); hence, changes in cell lineages in 
the tumors are unlikely to account for the observed defect in 
matrix assembly. Thus, these results strongly suggest that lack 
of CD98hc resulted in a marked reduction in Fn matrix forma-
tion in vivo.
Because Fn is required for vascular development, we ex-
amined the blood vessels formed in the teratocarcinomas (Fig. 
1 B) by whole-mount staining with endothelial cell–specifi  c 
fl  uorescent-labeled lectin. We also visualized pericytes/smooth 
muscle cells and endothelial cells on these tumors by detection 
of the specifi  c markers α-smooth muscle actin and platelet/
endothelial cell adhesion molecule 1 (PECAM-1), respectively 
(Fig. 1 C). In the CD98hc-null tumors, endothelial cells were 
present but failed to form intact blood vessels (Fig. 1 B) or to 
invest with α-smooth muscle actin–expressing cells (Fig. 1 C). 
Instead of associating with endothelial cells, α-smooth muscle 
actin–expressing cells were dispersed throughout the tumors. 
In sharp contrast, WT tumors exhibited an organized network 
of blood vessels, including larger vessels with an endothelial 
lining and smooth muscle cell–containing intima and media 
(Fig. 1, B and C). Thus, the absence of CD98hc impairs Fn 
matrix deposition and vascular development, a process known 
to depend on Fn.
Lack of CD98hc impairs Fn matrix 
assembly in vitro
To learn whether CD98hc defi  ciency by itself leads directly to 
defective cellular Fn matrix formation and to understand the 
mechanisms by which CD98hc supports Fn matrix formation, 
we developed conditional CD98hc-null mouse embryonic fi  -
broblasts (MEFs; Fig. 2, A and B). CD98hc conditional–null 
mice were generated as described in Materials and methods. 
We deleted CD98hc in vitro by infecting these cells with adeno-
viruses expressing Cre recombinase, resulting in 95% ex-
cision of exons 1 and 2 of CD98hc (Fig. 2 B). These cells 
were then mass sorted with immunomagnetic beads to select 
fi  broblasts lacking detectable CD98hc (Fig. 2 C). Importantly, 
the CD98hc-null fi  broblasts and parental WT cells expressed 
similar quantities of integrins α5, β1, α6, and αv, as judged by 
fl  ow cytometry (Fig. 2 C) and showed defects in integrin sig-
naling similar to those seen in CD98hc-null fi  broblasts derived 
from ES cells (Fig. S1, available at http://www.jcb.org/cgi/
content/full/jcb.200705090/DC1). None of the cells expressed 
Figure 2. Characterization of CD98hc-
conditional allele. (A) Conditional allele strat-
egy. Representation of WT CD98hc locus and 
the targeted allele after CRE recombination (see 
Materials and methods). LoxP sites are depicted 
as triangles and Flp sites as ovals. (B) PCR anal-
ysis of genomic DNA after CRE recombination 
on MEFs. After the recombination   occurred, 
CD98hc exons 1 and 2 were deleted. Expected 
sizes are 1.9 kb (ﬂ  oxed or WT allele; i.e., 
before CRE) and 382 bp (knockout allele; i.e., 
after CRE). (C) Flow cytometry analysis of cell 
surface expression of endogenous CD98 and 
of integrin subunits in CD98hc-deﬁ  cient cells. 
WT cells are shown in dotted line and CRE cells 
in ﬁ  lled histogram. These FACS data show de-
letion of CD98hc in CRE cells (i.e., CD98hc 
null) and no change in integrin repertoire as a 
result of this deletion. Control is staining with 
irrelevant IgG.JCB • VOLUME 178 • NUMBER 4 • 2007  704
a detectable amount of α1, α2, α4, or β3 integrins. Thus, these 
conditional CD98hc MEFs provide a tool to analyze the effect 
of CD98hc deletion on Fn matrix formation and integrin sig-
naling by fi  broblasts.
To examine Fn matrix assembly, we cultured WT or 
CD98hc-null fi  broblasts and assessed matrix deposition by 
immunofl  uorescence. 48 h after plating, WT cells exhibited 
abundant Fn fi  brils, whereas CD98hc-null cells (Fig. 3 A, green) 
were devoid of Fn fi  brils (Fig. 3 A). Similar differences were 
observed regardless of whether the cells were subconfl  uent 
(Fig. 3 A) or confl  uent (not depicted). The lack of matrix was 
confi  rmed biochemically, by assaying the formation of deoxy-
cholate (DOC)-insoluble Fn (Fig. 3 B), which was dramati-
cally reduced in the confl  uent CD98hc-null fi  broblasts. Because 
reduced assembly was observed in confl  uent  CD98hc-null 
cells, the lack of matrix in these cells cannot be ascribed to re-
duced cell density (Wierzbicka-Patynowski and Schwarzbauer, 
2003). Cell-associated Fn is present in fi  broblast cultures in 
two separate pools, distinguishable on the basis of their solu-
bility in DOC. One pool contains cell-bound DOC-soluble 
Fn, whereas the other one contains matrix-associated DOC-
insoluble Fn. Fn matrix assembly proceeds by the binding of 
Fn to cells in the DOC-soluble pool with subsequent transfer 
and accumulation of assembled Fn in the DOC-insoluble pool 
(McKeown-Longo and Mosher, 1983). Although there was at 
least a 20-fold reduction in the DOC-insoluble Fn with the 
CD98hc-null cells (Fig. 3 B, left), there was only a modest, 
approximately twofold reduction in the DOC-soluble cell-
bound Fn (Fig. 3 B, middle) and no decrease Fn in the condi-
tioned medium (Fig. 3 B, right) compared with WT cells. Thus, 
CD98hc deletion leads to defective Fn matrix assembly, and the 
defect appears to be at the step of transfer from the DOC-soluble 
to -insoluble pool.
CD98hc-null cells’ lack of Fn matrix 
is not due to reduced Fn biosynthesis 
or integrin afﬁ  nity
Because CD98hc participates in amino acid transport (Deves 
and Boyd, 2000), we considered the possibility that CD98hc de-
fi  ciency reduced the biosynthesis of Fn. To assess the availabil-
ity of endogenous soluble Fn, we cultured the cells in medium 
containing Fn-depleted FBS (Fig. 4 A). Roughly twofold greater 
quantities of secreted soluble Fn were detected in the condi-
tioned medium of CD98hc-null cells cultured in Fn-depleted 
medium (Fig. 4 A, left), and a profound reduction in DOC-
insoluble Fn matrix was evident (Fig. 4 A, middle). This result 
suggests that both cell types produce similar quantities of Fn, 
but CD98hc-defi  cient cells cannot assemble the Fn, resulting in 
the increase in the conditioned medium. Furthermore, when we 
supplemented the cell cultures with an excess of plasma Fn, the 
CD98hc-null cells still failed to assemble a matrix (Fig. 4 B). 
Thus, CD98hc is required for Fn matrix assembly, but not for 
Fn synthesis or secretion, and the lack of assembly in CD98hc-
null cells is not due to reduced Fn availability.
Matrix assembly requires that Fn fi  rst binds to high affi  n-
ity (operationally defi  ned as activated) integrins, such as α5β1, 
αIIbβ3, or αVβ3 (Wu et al., 1995a,b; Sechler et al., 1997, 2000). 
To assess the effect of CD98hc deletion on the affi  nity of Fn 
binding integrins in these MEFs, we examined their binding to 
a recombinant-soluble cell binding domain of Fn, composed 
of type 3 repeats 9–11 (3Fn[9–11]). The absence of CD98hc 
had no effect on the ability of the cells to bind to 3Fn(F9–11), 
a direct measure of the affi  nity of Fn binding integrins, such as 
integrin α5β1 (Chou et al., 2003). Importantly, when incubated 
with an activating anti–β1 integrin antibody, 9EG7, there was 
a marked increase in 3Fn(9–11) binding to both the WT and 
the null cells (Fig. 4 C); however, this enforced activation of 
Figure 3.  Deletion of CD98hc blocks Fn assembly in vitro. 
(A) WT (left) and CD98hc-deﬁ  cient (right) MEFs were incu-
bated for 48 h on 4 μg/ml Fn-coated coverslips. Fixed cells 
were stained for Fn (green) and actin (red). Nuclei appear 
blue. Note the absence of Fn ﬁ  brils in the CD98hc-null cells. 
Bars, 25 μm. (B) Fn assembly was also evaluated biochemi-
cally by analyzing the DOC-soluble and -insoluble portions of 
the cell matrix in both WT and CD98hc-null MEFs. Cells were 
cultured in complete medium (i.e., containing Fn). CD98hc-
null MEFs were impaired in their ability to incorporate Fn in 
both their DOC-insoluble and -soluble pools in the presence of 
exogenous Fn. Level of Fn in the conditioned medium was 
similar for both WT and CD98hc-null cells.CD98HC (SLC3A2) AND FIBRONECTIN MATRIX • FÉRAL ET AL. 705
integrins did not rescue Fn assembly by the CD98hc-defi  cient 
cells (Fig. 4 D). Thus, the CD98hc-null cells’ failure to assem-
ble matrix is not due to a defect in their ability to synthesize or 
secrete Fn or to bind to soluble Fn with high affi  nity.
CD98hc mediates RhoA-driven traction 
forces on the extracellular matrix
Fn must be conformationally altered to initiate assembly into 
fi  brils (Wierzbicka-Patynowski and Schwarzbauer, 2003). Once 
Fn binds to integrins, and the integrins connect to the cytoskele-
ton, RhoA-mediated cellular contractility exerts force on the 
Fn, leading to these conformational changes (Zhang et al., 1994; 
Zhong et al., 1998). We therefore examined the role of CD98hc 
in cellular contractility by assaying the contraction of an Fn-
 fi brin provisional matrix. Fibrin clots formed from blood plasma 
contain covalently cross-linked Fn that serves as a ligand for 
integrin  α5β1–dependent matrix contraction (Corbett and 
Schwarzbauer, 1999). Incorporation of WT MEFs in these ma-
trices led to a 52 ± 0.8% contraction after 2 h (Fig. 5, A and B). 
In contrast, contraction was markedly reduced when CD98hc-null 
cells were incorporated in the clot (24 ± 0.55% clot contraction). 
These cells lack β3 integrins, suggesting that the contraction 
was mediated by Fn binding β1 integrins, such as α5β1. In-
deed, clot retraction was strongly inhibited by a function-
blocking anti–mouse β1 antibody (clone Ha2/5; 18 ± 0.2 vs. 
52 ± 0.8% clot contraction; unpublished data). Thus, CD98hc 
mediates the β1 integrin–dependent contraction of an Fn-
 fi brin matrix.
The fi  nding that CD98hc was required for effi  cient clot 
contraction suggests that it mediates the generation of traction 
force on the extracellular matrix, a critical requirement for Fn 
assembly (Zhong et al., 1998). To examine this question, we 
used displacement of embedded fl  uorescent microbeads in fl  ex-
ible polyacrylamide substrates as a direct measure of traction 
forces (Beningo and Wang, 2002). Subconfl  uent MEFs were 
seeded for 2 h on Fn-coated polyacrylamide substrates in 
  serum-free medium. Deformation of substrate caused by cellular 
traction forces was detected by tracing the displacement of fl  uor-
escent beads, and displacement vector maps, or strain maps, 
were generated (Fig. 5 C, green). The resulting strain maps 
demonstrated a marked reduction in traction forces exerted by 
CD98hc-defi  cient MEFs compared with WT cells (Fig. 5 C). 
Figure 4.  CD98hc-null cells’ loss of assembly is not due to 
deﬁ  cient Fn biosynthesis or reduced integrin afﬁ  nity. (A) Fn 
biosynthesis was evaluated biochemically as described in 
Fig. 3. Levels of soluble Fn produced by WT and CD98hc-null 
cells (conditioned medium) were analyzed. Cells were cul-
tured in Fn-depleted medium (Fn−). Both WT and CD98hc-
null MEFs produced Fn, although only WT cells were able to 
assemble it into ﬁ  brils. Basal medium (Fn+) refers to complete 
Fn-containing medium. (B) WT (left) and CD98hc-deﬁ  cient 
(right) MEFs were incubated for 48 h in the presence of 
25 μg/ml exogenous soluble Fn. Fixed cells were stained for Fn 
(green), actin (red), and nucleus (blue). Addition of soluble Fn 
to CD98hc-null cell culture did not rescue Fn assembly. (C) Ef-
fect of activating anti-β1 mAb (9EG7) on α5β1 integrin bind-
ing to soluble Fn. Binding to the soluble cell binding domain 
of Fn (Fn 9–11) in the absence (−9EG7), and in the presence 
(+9EG7) of β1 activating antibody, are illustrated for WT 
(ﬁ   lled bars) and CD98hc-deﬁ   cient (open bars) cells. Error 
bars indicate SEM. (D) WT (left) and CD98hc-deﬁ  cient (right) 
MEFs were incubated for 48 h in the presence of 10 μg/ml 
activating β1 integrin mAb, 9EG7. Fixed cells were stained 
for Fn (green), actin (red), and nucleus (blue). Treatment of 
CD98hc-null cells with activating β1 mAb did not rescue Fn 
assembly in vitro. Note the presence of perinuclear intracellu-
lar staining for Fn in the CD98hc-null cells, consistent with Fn 
biosynthesis. Bars, 25 μm.JCB • VOLUME 178 • NUMBER 4 • 2007  706
There was about a threefold reduction in integrated strain for 
CD98hc-null cells compared with WT (0.77 vs. 2.5 pixels/area 
[arbitrary units], respectively; see Materials and methods). 
Thus, CD98hc-null cells are defective in the capacity to exert 
traction forces on the underlying substrate,
The small GTP binding protein RhoA is a major regulator 
of cell contractility (Chrzanowska-Wodnicka and Burridge, 1996; 
Hall, 1998) that provides the traction forces to initiate Fn matrix 
assembly (Zhong et al., 1998). Matrix assembly within tissues 
occurs when cells are in contact with surrounding 3D extracellu-
lar matrix, leading us to examine the effect of CD98hc deletion 
on adhesion-mediated alterations in RhoA activity when cells 
interact with 3D matrix (Cukierman et al., 2001). 30 min after 
adhesion of WT MEFs to a 3D matrix, RhoA activity decreased, 
followed by a secondary increase as previously described (Ren 
et al., 1999). In sharp contrast, the CD98hc-null cells did not show 
this late increase in RhoA activity (Fig. 6 A). Strikingly, both 
CD98hc-null and WT MEFs exhibited similar increases in RhoA 
activity in response to lysophosphatidic acid (LPA), an agonist 
that activates RhoA via G protein–coupled receptors (van Corven 
et al., 1989; Fig. 6 B). Thus, CD98hc is required for RhoA activa-
tion in response to cell adhesion to a 3D Fn matrix.
As noted, LPA induced RhoA activation in CD98hc-null 
MEFs, and activation of RhoA stimulates contractility, leading to 
the assembly of Fn by a variety of fi  broblastic cells (Checovich 
and Mosher, 1993; Zhang et al., 1994; Kranenburg et al., 1997). 
Consistent with the capacity of LPA to induce RhoA activation in 
CD98hc-null MEFs, addition of LPA enabled CD98hc-defi  cient 
MEFs to contract a Fn-fi  brin matrix (matrix contraction: WT, 
32 ± 1.1%; CD98hc null, 10 ± 0.2%; LPA-treated CD98hc null, 
52 ± 0.7%; Fig. 6 C). Similarly, LPA treatment enabled CD98hc-
defi  cient cells to assemble an Fn matrix as assessed by quantify-
ing formation of DOC-insoluble Fn (CD98hc null, 38 ± 6.3%; 
LPA-treated CD98hc null, 159 ± 3.3%, relative to WT MEFs; 
Fig. 6 D). Collectively, these data show that the reduced capacity 
of CD98hc-null cells to activate RhoA in response to extracellu-
lar matrix leads to their failure to assemble an Fn matrix.
The interaction of CD98hc with integrins 
mediates contraction of the extracellular 
matrix, thus regulating extracellular 
matrix assembly
The foregoing studies established that CD98hc participates in 
assembly of the Fn matrix by mediating adhesion-dependent 
RhoA activation that leads to traction on the extracellular matrix. 
Importantly, the CD98hc-null cells were able to activate RhoA 
in response to LPA, suggesting that matrix-driven RhoA activa-
tion is important in the assembly process. Integrins are the prin-
cipal receptors that lead to matrix-initiated biochemical signals 
(Ingber, 1991; LaFlamme and Auer, 1996), and we previously 
found that the physical interaction of CD98hc with integrins is 
required for effi  cient integrin signaling (Féral et al., 2005). To 
examine the role of CD98hc–integrin interaction in matrix as-
sembly, we reconstituted CD98hc-null MEFs with retroviruses 
encoding chimeras (Féral et al., 2005) formed between CD98hc 
and another type II transmembrane protein, CD69 (Fig. 7); each 
was well expressed as judged by fl  ow cytometry (Fig. 7 B). The 
C98T98E69 (cytoplasmic domain CD98hc, transmembrane do-
main CD98hc, and extracellular domain CD69) chimera inter-
acts with integrins, whereas C69T98E98 and C98T69E98 do 
not associate with integrins. Only the integrin binding chimera 
(C98T98E69) rescued the defect in Fn matrix assembly (Fig. 
7 A) and contractility (Fig. 7 C). CD98hc-defi  cient cells ex-
pressing the chimera that binds to integrins (C98T98E69) 
were able to induce a clot contraction (56 ± 1%) even more 
effi  ciently than WT cells (37 ± 0.8%). Thus, the capacity of 
Figure 5.  CD98hc mediates cellular traction forces on the 
extracellular matrix. (A) WT and CD98hc-deﬁ  cient  MEFs 
were mixed with 200 μl of Fn-containing platelet-poor plasma, 
200 μl of 28 mM CaCl2, and 5 U/ml human thrombin in 
Hepes-DME. Tubes were incubated for 2 h at 37°C. Depicted 
are digital images of WT and CD98hc-null clots. (B) Quantiﬁ  -
cation of the percentage of clot contraction is presented (see 
Materials and methods). Values represent the mean ± SEM of 
triplicate determinations. The assay was repeated three times 
with similar results. (C) Decreased cellular traction forces in 
CD98-deﬁ  cient MEFs. WT and CD98hc-deﬁ  cient MEFs were 
plated on a 120-kD fragment of Fn-coated polyacrylamide 
sheets, in which ﬂ  uorescent beads were embedded, as de-
scribed in Materials and methods. Strain maps (green) over-
laid with the brightﬁ  eld images of WT (top) and CD98hc-null 
(bottom) cells plated on 120-kD Fn-coated polyacrylamide 
substrate (gray). CD98hc-deﬁ  cient cells demonstrate reduced 
traction forces compared with WT cells. Bars, 10 μm.CD98HC (SLC3A2) AND FIBRONECTIN MATRIX • FÉRAL ET AL. 707
CD98hc to mediate contraction of an Fn-fi  brin clot depends on 
its ability to interact with integrins.
Discussion
Fn matrix assembly can be conveniently divided into three 
steps. First, Fn binding integrins must be activated to bind Fn 
with high affi  nity (Wu et al., 1995c; Sechler et al., 1997). 
Recent studies (Tadokoro et al., 2003; Kuo et al., 2006) establish 
that integrin activation is mediated by talin binding to the inte-
grin β cytoplasmic domain. Second, the integrins must connect 
to the actin cytoskeleton (Ali et al., 1977; Mautner and Hynes, 
1977; Wu et al., 1995c), a connection that can be mediated by 
talin (Brown et al., 2002; Jiang et al., 2003). Third, cellular 
contractility exerts force on the integrin-bound Fn, deforming 
it and leading to the initiation of Fn matrix assembly (Zhang 
et al., 1994; Zhong et al., 1998). Here, we show that CD98hc 
participates in Fn matrix assembly and that it does so by physically 
associating with integrins to mediate matrix-driven activation 
of RhoA and the resulting cellular contractility that exerts force 
on the matrix.
The variable expression of CD98hc and its contribution to 
Fn assembly have implications for the relationship between cell 
proliferation and formation of the extracellular matrix. CD98hc 
expression is tightly regulated coordinately with cell prolifera-
tion (Diaz et al., 1997), a pivotal event in wound healing, tumor-
igenesis, and development. Repair of skin wounds depends on 
precisely controlled formation of a fi  brous extracellular matrix. 
The extracellular matrix deposition correlates with proliferation 
of fi  broblasts and endothelial cells within the damaged area 
(Midwood et al., 2004). The dramatic up-regulation of CD98hc 
in proliferating cells could thus serve to promote Fn matrix 
assembly in healing wounds; conversely, a failure to down-
regulate CD98hc could lead to excess matrix deposition and cell 
proliferation, as seen in fi  brosis and keloid scars (Muir, 1990). 
Similarly, the marked up-regulation of CD98hc in tumors (Deves 
and Boyd, 2000) could contribute to enhanced formation of Fn 
extracellular matrix, thus altering the microenvironment of cells 
during tumorigenesis (Weaver et al., 1996; Lelievre et al., 1998; 
Schmeichel et al., 1998; Bissell et al., 2002; Weaver and Gilbert, 
2004). Moreover, we show that CD98hc mediates cell contrac-
tility, an event strongly associated with progression of some tu-
mors (Paszek et al., 2005). Finally, the deposition of Fn along 
the blastocoele roof is reported to be a critical step in gastrula-
tion (Boucaut et al., 1985) and later for morphogenetic move-
ments driven by convergent extension (Davidson et al., 2006). 
This spatiotemporally regulated matrix assembly is controlled 
by the activity of cellular integrins, as manifested by their ability 
to promote cell spreading (Ramos and DeSimone, 1996; Ramos 
et al., 1996), a CD98hc-dependent process (Féral et al., 2005). 
Thus, the importance of Fn matrix assembly in development and 
the role of CD98hc in matrix assembly shown here provide a 
cogent explanation for the early embryonic lethality of CD98hc 
gene disruption ( Tsumura et al., 2003) and suggest that changes 
in CD98hc expression, or its association with integrins, may 
 infl  uence a wide range of developmental processes through the 
regulation of Fn matrix assembly.
Materials and methods
Fn staining on tumor sections
A suspension of ES cells (1.5 × 10
6 cells per site) was injected subcutaneously 
into athymic BALB/c wehi nude mice. After 33 d, tumors were ﬁ  xed in 10% 
formaldehyde, parafﬁ  n embedded, sectioned, and stained for Fn with a rab-
bit polyclonal antibody against human Fn (Sigma-Aldrich). Alexa Fluor 546 
Figure 6.  CD98hc mediates adhesion-induced RhoA activation and matrix 
contraction to enable Fn matrix assembly. (A) RhoA activity was measured in 
an ELISA-based Rho assay in WT and CD98hc-deﬁ  cient cells after plating on 
a 3D Fn matrix. The error bars represent SEM. The assay was repeated three 
times with similar results. Samples were also resolved by SDS-PAGE and 
immunoblotted with anti-RhoA antibody (total RhoA) to conﬁ  rm that both WT 
and CD98hc-null MEFs express similar amounts of total RhoA (not depicted). 
(B) Activation of RhoA by LPA in WT and CD98hc-null MEFs. Adherent 
serum-starved CD98hc-null cells were treated with 1 μg/ml LPA or buffer, 
and RhoA activity was measured after 5 min. Values represent the mean and 
range of duplicate determinations. The assay was repeated twice with similar 
results. (C) Activation of RhoA bypasses the defect in matrix contraction in 
CD98hc-null cells. Clot contraction was measured 1 h after WT, CD98hc-null, 
and CD98hc-null MEFs were stimulated with LPA (see Materials and methods 
for details). Values represent the mean ± SEM of triplicate determinations. 
Depicted is one of two such experiments with identical results. (D) Activation 
of RhoA bypasses the defect in Fn matrix assembly in CD98hc-null cells. 
DOC-insoluble Fn produced by WT, CD98hc-null, and CD98hc-null MEFs 
treated with LPA was evaluated biochemically as described in Fig. 3. 
CD98hc-null MEFs stimulated with LPA were able to assemble Fn into ﬁ  brils 
as efﬁ  ciently as WT cells. Depicted are the means of triplicate measurements. 
The assay was repeated two times with similar results.JCB • VOLUME 178 • NUMBER 4 • 2007  708
goat anti–rabbit IgG (H+L; Invitrogen) was used as a secondary antibody. 
Sections were counterstained with the nuclear dye YOPRO-1 (Invitrogen).
Whole-mount lectin staining
Tumor samples were ﬁ  xed in 10% formaldehyde for 30 min at room tem-
perature, washed in 1× PBS containing 0.1 g/liter CaCl2, and cut into 
small (2 mm
3) tissue blocks. The tissue blocks were then incubated in the 
calcium-containing PBS in the dark for 48 h at 4°C in the presence of 10 
μg/ml isolectin GS-IB4 Alexa Flour 568 conjugate (Invitrogen). After wash-
ing, the stained tissues were analyzed using a laser-scanning confocal 
microscope (1024 MRC; Bio-Rad Laboratories, Inc.). Z-serial images were 
merged using Lasersharp software (Bio-Rad Laboratories, Inc.) to obtain a 
3D impression of the tumor samples.
Sequential immunohistoﬂ  uorescence
4-μm tissue sections were deparafﬁ  nized and treated with methanol con-
taining 0.3% H2O2 for 30 min at room temperature. Antigen retrieval and 
staining were performed using standard procedures. In brief, sections were 
ﬁ  rst stained for α-smooth muscle actin using mouse anti–human α-smooth 
muscle actin antibody (clone 1A4; DakoCytomation) diluted at 1:50 in PBS 
containing 3% BSA and 0.01% Tween 20 for 60 min at room temperature. 
After washing, sections were incubated with secondary antibody goat anti–
mouse Alexa 546 (Invitrogen) at 1:500 in PBS containing 0.01% Tween 20. 
Second, the TSA kit (PerkinElmer) was used for PECAM-1 staining using 
puriﬁ  ed rat anti–mouse PECAM-1 mAb (BD Biosciences). The bound anti-
bodies were detected using biotin-conjugated rabbit anti–rat (Vector Labo-
ratories) in combination with Streptavidin-FITC antibody (Vector Laboratories). 
Sections stained as above but in the absence of the primary antibodies 
served as the negative controls.
Generation of CD98hc-conditional cells
A P1 mouse ES cell clone containing the CD98hc gene was isolated from 
a 129Sv/J mouse library by PCR screening (Genome Systems, Inc.). The 
targeting vector consisted of a 1.4-kb 5′ homologous region and a 4.9-kb 
3′ homologous region. The region of exon 1, encoding the transmembrane 
domain of CD98hc, was ﬂ  anked with loxP site. A neomycin selection cas-
sette ﬂ  anked by Flp sites (provided by H. Beggs and G. Martin, University 
of California, San Francisco, San Francisco, CA) was inserted in intron 2. 
The linearized targeting construct was electroporated into R1 ES cells. 
G418-resistant colonies were selected for 7 d. Two homologous ES cell 
recombinants were identiﬁ  ed by PCR analysis (forward primer A, 5′-G  A  T  A-
G  A  C  G  G  G  A  G  T  A  T  T  C  A  G  C  G  A  G  G  C  -3′; and reverse primer B, 5′-C  T  C  A  T  G-
G  T  G  C  C  T  G  C  A  G  A  A  A  C  G  G  -3′) and conﬁ  rmed by Southern blotting. PCR 
products were obtained at the expected size: 248 bp for WT allele and 
304 bp for conditional knockout allele. These clones were karyotyped and 
subsequently injected into E3.5 C57BL/6 host blastocysts. The blastocysts 
were then transferred into pseudopregnant foster females. A total of seven 
chimeric males (distinguished by coat color) were obtained and bred to 
WT C57BL/6 females. Germ line offspring were genotyped by preparing 
DNA from tail biopsy for the presence of the targeted allele. Heterozy  gote 
males were identiﬁ  ed by PCR analysis. Homozygote CD98hc-  conditional 
knockout mice were bred onto human β-actin FLPe deleter strain (The Jackson 
Laboratory) to excise the neomycin selection cassette. Mice were housed 
in the University of California, San Diego, animal facility, and experiments 
Figure 7.  CD98hc–integrin interaction mediates Fn assembly. 
(A) CD98hc-deﬁ  cient MEFs reconstituted with each chimera 
depicted in B (C98T69E98, C69T98E98, or C98T98E69) 
were treated as described in Fig. 3 A. Fixed cells were stained for 
Fn (green), actin (red), and nucleus (blue). Only C98T98E69 
rescued CD98hc-deﬁ  cient cells’ ability to assemble Fn ﬁ  brils. 
Bars, 25 μm. (B) Expression and schematic of the chimeras 
used in A. CD98hc protein is depicted in black and CD69 in 
gray. Each chimera is deﬁ  ned by its cytoplasmic (C), trans-
membrane (T), or extracellular (E) domain derived from either 
CD98hc (98) or CD69 (69). CD98hc extracellular domain is 
necessary and sufﬁ  cient for amino acid transport, whereas 
the intracellular and transmembrane domains are required 
for interactions with integrins (Fenczik et al., 2001). Flow 
cytometry analysis (right) of cell surface expression of exog-
enous chimeras in CD98hc-deﬁ  cient cells (ﬁ  lled histogram) is 
shown. Control staining (empty histogram) was performed with 
irrelevant IgG. (C) CD98–integrin association is required for 
contraction of the extracellular matrix. WT, CD98hc-  deﬁ  cient, 
and CD98hc-deﬁ  cient MEFs reconstituted with C98T98E69 
were mixed with 200 μl of Fn-containing platelet-poor plasma, 
200 μl of 28 mM CaCl2, and 5 U/ml human thrombin in 
Hepes-DME. Tubes were incubated for 1 h at 37°C. Depicted 
are digital pictures of clots, as well as the calculated percent-
age of clot contraction (see Materials and methods). Values 
represent the mean ± SEM of triplicate determinations.CD98HC (SLC3A2) AND FIBRONECTIN MATRIX • FÉRAL ET AL. 709
were approved by the University of California, San Diego, Institutional Animal 
Care and Use Committee.
Cell culture
MEFs were derived from CD98hc-conditional knockout homozygote em-
bryos. MEFs were cultured in complete DME high glucose (Invitrogen), sup-
plemented with 10% FBS (HyClone), 20 mM Hepes, pH 7.3 (Invitrogen), 
0.1 mM nonessential amino acid (Invitrogen), 0.1 mM β-mercaptoethanol 
(Invitrogen), and 2 mM L-Glutamine (Invitrogen). The CD98hc-null MEFs 
were generated by infecting CD98hc-conditional knockout MEFs with ad-
eno-CRE encoding CRE recombinase. Viral titers ranged from 0.6 to 1.2 × 
10
12 U/ml. CD98hc deletion was detected by PCR (forward primer A, see 
the previous section; and reverse primer C, 5′-C  A  G  G  G  T  T  C  T  G  T  G  T  A  T  G  T  G-
G  G  C  G  G  -3′) and conﬁ  rmed by ﬂ  ow cytometry. Cells were stimulated with 
2 μg/ml (unless otherwise mentioned) LPA (1-oleoyl-2-hydroxy-sn-glycero-3 
phosphate, monosodium salt) as described elsewhere (Zhong et al., 1998). 
In brief, MEFs were plated at 1 million per 10-cm Petri dish and treated 
every 4–5 h for 18 h (starting 24 h after plating). The reconstituted cells were 
generated by infecting CD98hc-null MEFs with pBabe-Puromycin retrovirus 
encoding or CD98hc/CD69 chimeras (Fenczik et al., 2001). Viruses were 
generated in EcoPack 293 cells (CLONTECH Laboratories, Inc.), and viral 
titers ranged from 0.9 to 1.7 ×10
6 U/ml. After puromycin selection, chi-
mera expression was conﬁ  rmed by ﬂ  ow cytometry.
Visualizing/imaging Fn assembly
MEFs were seeded in 1% FBS at 10,000 cells/well in 24-well plates onto 
12-mm coverslips coated with 4 μg/ml Fn and blocked with 0.5% BSA. 
Where indicated, either 25 μg/ml of exogenous plasma Fn or 10 μg/ml 
of activating anti-β1 mAb, 9EG7, was added to the culture medium. After 
48 h in culture, the cells were ﬁ  xed with 2% PFA in PBS for 20 min and 
permeabilized for 10 min with 0.05% Triton X-100. Fixed cells were 
washed with PBS, and nonspeciﬁ  c sites were blocked with 3% BSA before 
the addition of primary antibody (rabbit anti-Fn [Sigma-Aldrich]; 1:2,000) 
for 2 h at 37°C. Speciﬁ  c binding was detected using goat anti–rabbit anti-
body conjugated with Alexa 488 (Invitrogen). The actin cytoskeleton was 
visualized by incubating with rhodamine-conjugated phalloidin while the 
nuclei were stained with DAPI (Invitrogen). Individual coverslips were 
mounted in aqueous mounting media with anti-fade (Gel Mount; Sigma-
Aldrich). Digital images were captured at room temperature with a charge-
coupled device camera (Orca ER; Hamamatsu) using a standard upright 
ﬂ  uorescent microscope (Axioplan 2 [Carl Zeiss MicroImaging, Inc.; Plan-
Neo Fluar 20× objective with 0.50 NA) controlled by the image capture 
and processing program Openlab (Improvision). Photoshop (Adobe) was 
used to increase the γ of images.
Biochemical assessment of Fn assembly
To assess the Fn assembly biochemically, the DOC-soluble and -insoluble 
portions of the cell matrix were analyzed as described previously (Zijlstra 
et al., 1999). In brief, MEFs were plated at 3 million cells per 10-cm Petri 
dish in complete medium (Fn+) or Fn-depleted medium (Fn−). Fn-depleted 
medium was generated by depleting Fn from the FBS using gelatin Sepha-
rose before preparing the medium (Zijlstra et al., 1999). The cells were 
incubated for 48 h, at which time the conditioned medium was collected. 
The cell monolayer was washed with 3× PBS and lysed in 2 ml 3% DOC, 
50 mM Tris, pH 8.8, and 0.1 mM EDTA, with protease inhibitors (com-
plete, mini protease inhibitor tablets; Roche) for 15 min at 4°C. The lysate 
was subsequently passed through a 23-gauge needle ﬁ  ve times and spun 
at 35,000 g for 20 min to remove the insoluble material. The soluble com-
ponent was kept for further analysis. The insoluble pellet was washed once 
with DOC lysis buffer and spun again. The pellet was solubilized in 50 μl 
reducing Laemmli buffer (62.5 mM Tris-HC1, pH 6.8, 1.5% SDS, 9% glyc-
erol, 50 mM dithiothreitol, and 0.005% bromophenol blue). Samples were 
separated by SDS-PAGE and analyzed by Western blotting using rabbit 
anti-Fn antibody (Sigma-Aldrich) followed by an HRP-conjugated goat 
anti–rabbit IgG (Jackson ImmunoResearch Laboratories), and bands were 
visualized by chemiluminescence (Pierce Chemical Co.). Intensities of bands 
were quantiﬁ  ed by scanning densitometry using ImageJ software.
Flow cytometry
Anti–mouse α1 (clone Ha 31/8), anti–mouse α2 (clone HMα2), anti–mouse 
α4 (PS/2), anti–mouse α5 (clone HMα5-1), anti–mouse α6 (clone GoH3), 
anti–mouse αv (clone RMV-7), anti–mouse β1 (clone 9EG7) integrin, and 
anti–mouse CD98 (clone H202-141) were purchased from BD Biosciences 
and used at the recommended concentrations. Goat FITC-conjugated anti–
rat IgG and goat FITC-conjugated anti–hamster IgG were obtained from 
Biosource International and were used as secondary antibodies for α4, 
α6, αv, and β1; murine CD98; and α1, α2, and α5 detection, respectively. 
Fn 9–11 binding was assayed by two-color ﬂ  ow cytometry as previously 
described (Hughes et al., 2002) in the presence or absence of 10 μg/ml 
of activating anti-β1 mAb 9EG7.
Fibrin clot retraction assay
This assay was performed by modiﬁ  cation of a published method (Ylanne 
et al., 1993). In brief, WT or CD98hc-deﬁ  cient MEFs were harvested with 
trypsin-EDTA (Invitrogen), quenched with complete medium, washed twice 
with PBS one time, and resuspended at 8.5 million cells per milliliter in 
serum-free DME (Invitrogen) buffered with 25 mM Hepes. 350 μl of this cell 
suspension was added to 7 × 45 mm siliconized glass cuvettes (Sienco, 
Inc.). Then, 200 μl of human platelet–poor plasma anticoagulated with 
ACD (85 mM sodium citrate, 65 mM citric acid, and 104 mM glucose) 
was added, followed by 200 μl Hepes-buffered DME containing 28 mM 
CaCl2 and 5 U/ml human thrombin (Sigma-Aldrich). Cuvettes were incu-
bated at 37°C with 5% CO2. Images were acquired with a digital camera 
at 1 or 2 h, and subsequently the 2D area of the clot was measured using 
ImageJ software. The percentage of clot contraction was calculated according 
to the following equation: percentage of clot contraction (t = 1 h) = 100
([area at t = 1 h/area at t = 0] × 100).
Cellular tension measurements
Polyacrylamide gels with embedded ﬂ  uorescent beads on coverslips were 
prepared using previously described protocol (Wang and Pelham, 1998) 
with some modiﬁ  cations (see the supplemental text, available at http://
www.jcb.org/cgi/content/full/jcb.200705090/DC1). Cell culturing, im-
age acquisition, and strain map construction were performed as follows. 
WT and CD98-deﬁ  cient MEFs were harvested with trypsin-EDTA (Invitro-
gen), quenched with complete medium, washed twice with 1× PBS, and 
resuspended at 0.1 million cells per milliliter in serum-free DME (Invitrogen) 
buffered with 25 mM Hepes. Cells were kept in suspension for 1 h at room 
temperature, and 20,000 cells were plated on a polyacrylamide sheet. 
After culturing on a polyacrylamide sheet for 2 h, images of both cell types 
were acquired within 10 min from each other. A microscope (TE2000; 
Nikon) equipped with environmentally controlled enclosure (37°C and 5% 
CO2), 60× 1.2 NA water objective (Olympus), motorized stage (Ludl), ex-
citation ﬁ  lter wheel (Ludl), ﬁ  lter set (Semrock), and camera (CoolSnap HQ; 
Roper Scientiﬁ  c) was used to acquire images of ﬂ  uorescent beads embed-
ded in polyacrylamide and brightﬁ  eld images of cells in six different ﬁ  elds. 
After addition of 200 μl RIPA buffer to 2 ml of media, cells detached and 
new images of the same ﬁ  elds were taken to collect reference data on 
beads’ location in nonstressed gel. Images of ﬂ  uorescent beads were ana-
lyzed using image analysis software written in Matlab (courtesy of G. 
Danuser’s and C. Waterman-Storer’s groups, The Scripps Research Insti-
tute, La Jolla, CA). Images were divided to 1.6-μm
2 areas, and displace-
ment vectors between were calculated (Ji and Danuser, 2005). Vectors 
(Fig. 5 C, green) on the strain map were increased ﬁ  ve times for visualiza-
tion purposes. Brightﬁ  eld and strain map images were superimposed using 
Photoshop (Adobe). Integrated strains were calculated by summing up the 
magnitudes (WT, 7,400 pixels; and CD98hc null, 1,444 pixels) of the 
strain vectors inside the cell mask and dividing them by the cell area (WT, 
2,945 arbitrary units; and CD98hc null, 1,873 arbitrary units).
Rho GTPase assay
WT and CD98hc-null MEFs were grown in 0.5% serum for 24 h and then 
in serum-free medium for another 17 h. Cells were detached and kept in 
suspension at room temperature for 1 h in serum-free medium. Serum-
starved cells were then plated on 3D Fn plates (3 million cells/plate), and 
RhoA activity was assayed at the indicated time points. For LPA treatment, 
cells were grown and serum starved as described, 1 μg/ml LPA was added 
to each plate, and RhoA activity was measured after a 5-min incubation. 
3D Fn matrix was prepared as described previously (Cukierman et al., 
2001) using NIH3T3 cells cultured in a 10-cm Petri dish. RhoA activity was 
measured using a commercially available ELISA-based assay (G-LISA; 
Cytoskeleton, Inc.) according to the manufacturer’s protocol. Lysates were 
also resolved by SDS-PAGE and immunoblotted with rabbit anti-RhoA 
(67B9) antibody (Cell Signaling), followed by a IRDye 800CW goat anti–
rabbit IgG (LI-COR Biosciences), and bands were visualized by scanning 
blots using an infrared imaging system (Odyssey; LI-COR Biosciences).
Online supplemental material
Fig. S1 shows that CD98hc contributes to the integrin-dependent activation 
of FAK and p130
CAS via its integrin binding domain by reconstitution JCB • VOLUME 178 • NUMBER 4 • 2007  710
experiments. The supplemental text provides additional methodological de-
tails for the cellular tension measurements and for the assessment of tyrosine 
phosphorylation. Online supplemental material is available at http://www
.jcb.org/cgi/content/full/jcb.200705090/DC1.
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